tbuckley/cabot-search huggingface dataset:
Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.
Authors: Toni K. Choueiri, Wanling Xie, Lauren Christine Harshman, Georg A. Bjarnason, Jennifer J. Knox, Mary J. MacKenzie, Lori Wood, Ulka N. Vaishampayan, Min-Han Tan, Sun Young Rha, Frede Donskov, Neeraj Agarwal, Christian K. Kollmannsberger, Scott A. North, Brian I. Rini, Daniel Yick Chin Heng
Journal: Journal of Clinical Oncology (2012)

358 Background: Survival estimates for patients with mRCC are traditionally reported from the time of TT initiation. These survival projections, however, may not be applicable to patients who have already survived a period of time after initiating therapy. CS accounts for elapsed time since starting therapy, providing more relevant prognostic information. Methods: Data on 1673 patients treated with first-line VEGF TT between 4/7/2003 and 10/12/2010 was analyzed. Median follow up for patients still alive is 20.1 months. Conditioned survival was calculated on the set of patients alive or on TT at 3 months and using 3 months increments for up to 18 months. Results: The 2-year CS probability tends to slightly improve from 44 to 51% when conditioned on having already survived 0 to18 months since initiation of TT, respectively. The Heng et al (JCO 2009) risk criteria (defined at therapy initiation) retains prognostic ability over time independent of previous survival time or previous time on TT up to 18 months (p&lt;0.0001 for all comparisons). In the subgroup analysis stratified by Heng risk groups, 2-year CS minimally changes over time in the favorable (FAV) and in the intermediate (INT) groups, but in the poor risk group, the 2-year CS improves from 11% initially to 33% after 18 months. When conditioned on time on TT, 2-year CS improves from 44% to 68% overall, from 74% to 90% in the FAV risk group, 49% to 57% in the INT risk group and 11% to 73% in the poor-risk group. Conclusions: Conditional survival may be a more relevant measure of prognosis for those who have already survived or have been on TT for a period of time. The largest improvement was seen in patients in the poor risk group. [Table: see text]
Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease.
Authors: Alison Rager, Steven C. Goldstein, Noelle Frey, Jennifer Davis, Michael Vozniak, Jacqueline Smith, Elizabeth Hexner, Alison Wakoff Loren, Selina Luger, Alexander Perl, Ran Reshef, Donald E Tsai, Edward A. Stadtmauer, David Porter
Journal: Blood (2009)
Treatment with Lenalidomide Has a Positive Immunomodulatory Effect in Patients with Chronic Lymphocytic Leukemia.
Authors: Hui Gao, Alessandra Ferrajoli, Evan N Cohen, Bang-Ning Lee, Sanda Tin, Susan O’Brien, William G. Wierda, Zeev Estrov, Stefan Faderl, Michael J Keating, James M. Reuben
Journal: Blood (2008)
Umbilical Cord Blood (UCB) Transplantation after Non-Myeloablative (NMA) Conditioning for Advanced Follicular Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia: Low Transplant-Related Mortality and High Progression-Free Survival.
Authors: Juliet N. Barker, Daniel J. Weisdorf, Todd E. DeFor, Claudio G. Brunstein, John E. Wagner
Journal: Blood (2005)
ABL1 Gene Amplification and Aberration Involving HOX11L2/TLX3 in T-Acute Lymphoblastic Leukemia (T-ALL).
Authors: Elisa Luño, Carmen Sanzo, Fermin Jonte, Regina LLorente, Emilia Fanjul, Soledad Gonzalez, Araceli Martínez
Journal: Blood (2006)
Use of Low Dose Oral Vitamin K in the Treatment of Patients with INR Values of More Than 10.0.
Authors: Mark A. Crowther, David Garcia, Walter Ageno, Daniel M. Witt, Sam Schulman, Mark Blostein, Michael J. Kovacs, Clive Kearon, David Anderson, Phil Wells, Jeff S. Ginsberg, Rita Selby, Luqi Wang, Susan R. Kahn
Journal: Blood (2005)
PCSM-05ANTIEPILEPTIC DRUG TREATMENT WITH BUCCAL CLONAZEPAM AND INTRANASAL MIDAZOLAM IN THE END OF LIFE PHASE OF GLIOMA PATIENTS: A FEASIBILITY STUDY
Authors: Johan Koekkoek, Tjeerd Postma, Jan Heimans, Jaap Reijneveld, Martin Taphoorn
Journal: Neuro-Oncology (2015)

BACKGROUND: A rapid deterioration in neurological functioning may hamper the oral administration of antiepileptic drugs (AEDs) in the end of life (EOL) phase of glioma patients. We aimed to assess the feasibility of treatment with non-oral AEDs in an out-of-hospital setting. METHODS: We included patients with a histopathological diagnosis of World Health Organization (WHO) grade II-IV glioma and a history of epilepsy, in whom further antitumor treatment was considered to be no longer meaningful. When swallowing difficulties developed, the patient's caregiver started to administer prophylactic AED treatment with buccal clonazepam. Acute seizures were treated with intranasal midazolam. We evaluated the adherence to the study medication, seizure prevalence as well as caregiver's satisfaction. RESULTS: Thirty-four patients were approached, of which 25 gave consent to participate and 23 had died at the end of the study. Fourteen of 19 patients (73.7%) who had developed swallowing difficulties used the study medication. Prophylactic buccal clonazepam was used by 13 patients, of which 8 patients remained seizure free until death. Six patients received treatment with intranasal midazolam at least once. In all patients seizure control could be reached. None of the patients had to be transferred to the hospital because of recurrent seizures. All caregivers reported satisfaction with the use of the study medication. CONCLUSIONS: It is feasible to treat glioma patients with seizures in the EOL phase with a combination of buccal clonazepam and intranasal midazolam. Additionally, it seems to provide an important level of comfort among caregivers to be able to manage seizures at home.
Analysis of SF3B1 in a Large Cohort of Refractory Anemia with Ring Sideroblasts with/without Marked Thrombocytosis (RARS-T/RARS) in an European Multicentre Study Reveals a High Incidence (86.3%) of Mutations and an Independent Favorable Association with Outcome
Authors: Susanne Schnittger, Ulrich Germing, Julien Broseus, Vera Grossmann, Tamara Alpermann, Lourdes Florensa Brichs, Eric Lippert, Francois Liferman, Sabine Jeromin, Torsten Haferlach, Francois Girodon
Journal: Blood (2012)
High-flow warm humidified oxygen versus standard low-flow nasal cannula oxygen for moderate bronchiolitis (HFWHO RCT): an open, phase 4, randomised controlled trial
Authors: Elizabeth Kepreotes, Bruce Whitehead, John Attia, Christopher Oldmeadow, Adam Collison, Andrew Searles, Bernadette Goddard, Jodi Hilton, Mark Lee, Joerg Mattes
Journal: The Lancet (2017)
Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO)
Authors: Ai-Ming Yu, Magnus Ingelman-Sundberg, Nathan J. Cherrington, Lauren M. Aleksunes, Ulrich M. Zanger, Wen Xie, Hyunyoung Jeong, Edward T. Morgan, Peter J. Turnbaugh, Curtis D. Klaassen, Aadra P. Bhatt, Matthew R. Redinbo, Pengying Hao, David J. Waxman, Li Wang, Xiao-bo Zhong
Journal: Acta Pharmaceutica Sinica B (2017)

Variations in drug metabolism may alter drug efficacy and cause toxicity; better understanding of the mechanisms and risks shall help to practice precision medicine. At the 21st International Symposium on Microsomes and Drug Oxidations held in Davis, California, USA, in October 2–6, 2016, a number of speakers reported some new findings and ongoing studies on the regulation mechanisms behind variable drug metabolism and toxicity, and discussed potential implications to personalized medications. A considerably insightful overview was provided on genetic and epigenetic regulation of gene expression involved in drug absorption, distribution, metabolism, and excretion (ADME) and drug response. Altered drug metabolism and disposition as well as molecular mechanisms among diseased and special populations were presented. In addition, the roles of gut microbiota in drug metabolism and toxicology as well as long non-coding RNAs in liver functions and diseases were discussed. These findings may offer new insights into improved understanding of ADME regulatory mechanisms and advance drug metabolism research.
Epstein-Barr Virus–induced Gene 2 Mediates Allergen-induced Leukocyte Migration into Airways
Authors: Zhong-Jian Shen, Jie Hu, Venkatesh P. Kashi, Elizabeth A. Kelly, Loren C. Denlinger, Kevan Lutchman, Jeffrey G. McDonald, Nizar N. Jarjour, James S. Malter
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rationale: Leukocyte recruitment to sites of allergic inflammation depends on the local production of priming cytokines, chemokines, and potentially other mediators. Previously, we showed that eosinophils (Eos) express numerous orphan G-protein–coupled receptors, including Epstein-Barr virus–induced gene 2 (EBI2). Despite its contribution to inflammatory diseases, the role of EBI2 in pulmonary eosinophilia is unknown.Objectives: To determine whether oxysterol ligands for EBI2 are increased in asthma exacerbation, and if or how they promote Eos pulmonary migration.Methods: EBI2 ligands and pulmonary eosinophilia were measured in the bronchoalveolar lavage fluid from patients with mild asthma 48 hours after acute allergen challenge. In vitro, the ability of EBI2 ligands alone or in combination with IL-5 priming to induce the migration of human blood Eos was assessed.Measurements and Main Results: EBI2 was constitutively and stably expressed in peripheral blood Eos. Eos treated with the EBI2 ligands showed significantly increased transwell migration that was enhanced by priming with physiologic doses of IL-5. Migration was suppressed by inhibitors of the prolyl isomerase Pin1 or extracellular signal–regulated kinases (ERK) 1/2 or by pertussis toxin. EBI2 signaling activated Pin1 isomerase activity through a cascade that was sensitive to ERK inhibitors and pertussis toxin. The concentration of EBI2 ligands was significantly increased in the bronchoalveolar lavage fluid 48 hours after segmental allergen challenge and strongly correlated with the increased numbers of Eos, lymphocytes, and neutrophils in the airways.Conclusions: Oxysterols are increased in inflamed airways after allergen challenge and, through G-protein subunit α, ERK, and Pin1 signaling, likely participate in the regulation of Eos migration into the lung in people with asthma.
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Authors: Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, Jean-Jacques Grob, Reinhard Dummer, Jedd D Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A Ascierto, Jon M Richards, Celeste Lebbé, Virginia Ferraresi, Michael Smylie, Jeffrey S Weber, Michele Maio, Andrew Bottomley, Srividya Kotapati, Veerle de Pril, Alessandro Testori, Alexander M M Eggermont
Journal: The Lancet Oncology (2017)
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Authors: Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M. G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha, Alvar Agustí
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Section:ChooseTop of pageAbstract <<IntroductionDefinition and Factors Th...Diagnosis and Initial Ass...Prevention and Maintenanc...Rehabilitation, Education...Supportive, Palliative, E...Other TreatmentsInterventional TherapyManagement of Stable COPDTreatment of Stable COPDMonitoring and Follow-upTreatment OptionsCOPD and ComorbiditiesReferencesCITING ARTICLES
HIV Care Outcomes Among Blacks with Diagnosed HIV — United States, 2014
Authors: Andre F. Dailey, Anna Satcher Johnson, Baohua Wu
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Since the release of the National HIV/AIDS Strategy (NHAS) (1) and the establishment of the federal Human Immunodeficiency Virus (HIV) Care Continuum Initiative (2), federal efforts have accelerated to improve and increase HIV testing, care, and treatment and to reduce HIV-related disparities in the United States. National HIV Surveillance System (NHSS)* data are used to monitor progress toward reaching NHAS goals,† and recent data indicate that blacks have lower levels of care and viral suppression than do persons of other racial and ethnic groups (3). Among persons with HIV infection diagnosed through 2012 who were alive at year-end 2013, 68.1% of blacks received any HIV medical care compared with 74.4% of whites (3). CDC used NHSS data to describe HIV care outcomes among blacks who received a diagnosis of HIV. Among blacks with HIV infection diagnosed in 2014, 21.9% had infection classified as HIV stage 3 (acquired immunodeficiency syndrome [AIDS]) at the time of diagnosis compared with 22.5% of whites; 71.6% of blacks were linked to care within 1 month after diagnosis compared with 79.0% of whites. Among blacks with HIV infection diagnosed through 2012 who were alive on December 31, 2013, 53.5% were receiving continuous HIV medical care compared with 58.2% of whites; 48.5% of blacks achieved viral suppression compared with 62.0% of whites. Intensified efforts and implementation of effective interventions and public health strategies that increase engagement in care and viral suppression among blacks (1,4) are needed to achieve NHAS goals.
Classification of Acute Myelogenous Leukemia (AML) Based on Patterns of Signal Transduction Pathway (STP) and Apoptosis Regulating Protein Activation Determined by Reverse Phase Proteins Arrays (RPPA).
Authors: Raoul Tibes, YiHua Qiu, Kevin R. Coombes, David Gold, Gordon B. Mills, Steven M. Kornblau
Journal: Blood (2005)
Alteration of the epigenome during carcinogenesis of intestinal-type gastric cancer.
Authors: Yong Sung Kim, Hee-Jin KIM, Keeok Haam, Tae-Wook Kang, Seon-Young Kim, Mirang Kim, Seung-Moo Noh, Kyu-Sang Song, Carlo Maley
Journal: Journal of Clinical Oncology (2012)

34 Background: Next-generation sequencing (NGS) is opening a new era for understanding how the human genome is altered in the process of cancer development. We sought to establish an epigenome map based on the DNA methylome during gastric carcinogenesis, paving the way to a better understanding of the origins of gastric cancer using NGS-based epigenome analysis. Methods: We purified DNA in laser-capture microdissected (LCM) cells of normal mucosa, intestinal metaplasia (IM), and gastric cancer from frozen samples of one patient with intestinal type gastric tumor. Two NGS-based epigenome analyses were performed on each DNA: ‘MBD-seq’ (methylated DNA binding domain sequencing) and ‘RRBS’ (reduced representation bisulfite sequencing). Results: MBD-seq and RRBS generated ~25.7 million and ~15.1 million reads respectively, per lane on average. The sequence data matched with 79% (21,514/27,191) and 55% (14,991/27,191) of promoter sequences from UCSC genome browser, respectively. We then identified about one thousand differentially methylated promoters (DMPs), which were altered in IM and in gastric cancer or in gastric cancer compared to that of gastric mucosa. In particular, hypomethylation was detected in 30 promoters by MBD-seq and 173 by RRBS, indicating that RRBS is highly informative for identifying hypomethylated DMPs associated with gene activation during carcinogenesis. Conclusions: We identified several novel hyper- or hypomethylated biomarkers for IM or gastric cancer using NGS-based epigenome analysis. Our reference epigenome map may provide a foundation for future studies exploring the prognostic or preventive biomarker for early stage of gastric cancer.
HDAC Inhibitors As Potential New Agents Improving the Efficacy of Monoclonal Antibodies
Authors: Malgorzata Bobrowicz, Michal Dwojak, Agata Malenda, Kamil Bojarczuk, Marta Siernicka, Beata Pyrzynska, Ewa Lech-Maranda, Tomasz Stoklosa, Magdalena Winiarska, Jakub Golab
Journal: Blood (2014)
PIP4KIIα Gene Silencing by Lentivirus-Mediated Delivery of shRNA in Human K562 Cells,
Authors: Tânia Regina Zaccariotto, Daniela Maria Ribeiro, Joao Machado-Neto, Magnun N N Santos, Carolina Lanaro, Dulcinéia Martins Albuquerque, Sara Teresinha Saad, Fernando Ferreira Costa, Maria de Fátima Sonati
Journal: Blood (2011)
Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California.
Authors: Adrian Stuart Fairey, Siamak Daneshmand, Tanya B. Dorff, Ryan Paul Dorin, Gary Leiskovsky, David I. Quinn, Anne Schuckman, Jie Cai, Gus Miranda, Eila C. Skinner
Journal: Journal of Clinical Oncology (2012)

301 Background: There is a paucity of data on neoadjuvant GC (gemcitabine, cisplatin) chemotherapy in patients with muscle-invasive bladder cancer (MIBC). Our aim was to compare pathologic and survival outcomes of neoadjuvant GC and M-VAC (methotrexate, vinblastine, doxorubicin, cisplatin) chemotherapy in patients with MIBC. Methods: A retrospective analysis of prospectively collected data from the University of Southern California (USC) Bladder Cancer Database was performed. Between 1985 and 2011, 116 patients received neoadjuvant chemotherapy prior to radical cystectomy and extended pelvic lymph node dissection for clinical stage T2-T4N0M0 bladder cancer. The outcomes were pathologic complete response (pT0N0), pathologic tumor downstaging (pT0N0, pTaN0, pT1N0, or pTisN0), overall survival (OS), and recurrence-free survival (RFS). The Kaplan-Meier method and Cox proportional regression models were used to analyze survival data. Results: The median follow-up duration was 4.5 years (range, 0 to 19.8 years). Fifty-eight patients each received GC and M-VAC chemotherapy. There were no statistically significant differences between the GC and M-VAC groups with regard to pathologic complete response (27.3% versus 17.1%, p=0.419) or pathologic tumor downstaging (45.5% versus 37.1%, p=0.498). The predicted 5-year OS (29% versus 38%, Log rank p=0.634) and RFS (36% versus 35%, Log-rank p=0.891) rates did not differ between the GC and M-VAC groups. However, in a subset of 37 patients with pathologic lymph node positive disease, the predicted 1-year RFS rate differed between the GC and M-VAC groups (0% versus 32%, log rank p=0.019). Multivariable analysis showed a trend toward an independent association between type of neoadjuvant chemotherapy and RFS (GC versus M-VAC: HR 1.64, 95% CI 0.93 to 2.89, p=0.089). Conclusions: Pathologic complete response, pathologic tumor downstaging, and survival did not differ in patients who received neoadjuvant GC and M-VAC chemotherapy. However, GC was associated with poorer RFS in a subset of patients with pathologic lymph node positive disease. Randomized controlled trials comparing neoadjuvant chemotherapy regimens are urgently needed.
A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy.
Authors: Adam S. Kotowski, Andrew Stegemann, Shabnam Rehman, Kristopher Attwood, Ellis Glenn Levine, Khurshid Guru, Donald L. Trump, Roberto Pili
Journal: Journal of Clinical Oncology (2012)

318 Background: Muscle invasive bladder cancer (MIBC) is a chemo-sensitive disease that responds to therapy before or after curative-intent radical cystectomy (RC). Neoadjuvant chemotherapy (NAC) improves overall survival by 5-8% in current meta-analyses. Adjuvant chemotherapy (AC) has shown benefit but is less rigorously tested. Methods: We retrospectively reviewed the cystectomy database at our institute from 2005-2011 and analyzed patients who have received NAC or AC for MIBC. The Log rank test was used to compare survival between groups and Cox regression models were used for adjusted comparisons of survival. Results: 45 patients (p) (13 NAC and 32 AC) were evaluated with a mean age of 65.5 years (50-82), including 77% males and 23% females. Patients were most commonly offered chemotherapy because of co-morbidities and performance status. NAC was most commonly gemcitabine (G)/cisplatin (n=9) and AC was usually G/platinum (n=27). Sixty-nine percent of patients were downstaged and 23% had a complete pathologic response following NAC. Three p in AC group had positive margins; all of these cases were T4 cancers. Pathologic staging showed 84% ≥T3 and 53% node positive disease. Patients receiving AC had a mean interval of 64.8 days (42-129) to the start of treatment. NAC and AC patients received median 4.1 (3-7) and 4.5 cycles (1-12), respectively, throughout entire course of treatment. The median overall survival (OS) was 24.5 months (m) (17.1 m-not reached) and 24-month survival rate was 47%. Progression free survival (PFS) was 12.3 m (8.5-23.5 m) for all patients. There was no difference for OS or PFS based on age, gender, time after surgery to first dose of therapy, or mode of therapy (NAC or AC). When adjusted for number of cycles completed, a trend toward improved median OS (not reached vs. 22 m p= 0.092 ) and a significant PFS improvement (28.5 vs 11.5 m p=0.026) with NAC vs. AC was observed. Grade 3-4 urologic toxicity was negligible in both groups, however the AC group had a higher percentage of grade 3-4 hematologic toxicity. Conclusions: Despite a small sample size, results from our series favor NAC based upon efficacy and tolerability for patients with locally invasive bladder cancer.
Dose-Adjusted EPOCH Plus Rituximab in Untreated Patients with Poor Prognosis Large B-Cell, with Analysis of Germinal Center and Activated B-Cell Biomarkers. A Phase IV Study Conducted by the Spanish PETHEMA Group
Authors: Noelia Purroy, Juan Bergua, Laura Gallur, Julio Prieto, Juan-Manuel Sancho, Luis Lopez, Jose A Garcia-Marco, Santiago Montes, Andres Lopez
Journal: Blood (2011)
The Dysfunction of Platelets in Paroxysmal Nocturnal Hemoglobinuria
Authors: Rong Fu, Yinping Meng, Yihao Wang, Hui Liu, Yi Liu, Lijuan Li, Shaoxue Ding, Erbao Ruan, Huaquan Wang, Guojin Wang, Jia Song, Zonghong Shao
Journal: Blood (2015)
The Eph-related tyrosine kinase ligand Ephrin-B1 marks germinal center and memory precursor B cells
Authors: Brian J. Laidlaw, Timothy H. Schmidt, Jesse A. Green, Christopher D.C. Allen, Takaharu Okada, Jason G. Cyster
Journal: The Journal of Experimental Medicine (2017)

Identification of germinal center (GC) B cells is typically reliant on the use of surface activation markers that exhibit a wide range of expression. Here, we identify Ephrin-B1, a ligand for Eph-related receptor tyrosine kinases, as a specific marker of mature GC B cells. The number of Ephrin-B1